Acyclic, Monocyclic, and Bicyclic Monoterpenes Group

These substances were identified for action under the Chemicals Management Plan (CMP). The screening assessment focuses on 15 substances, referred to collectively under the CMP as the Acyclic, Monocyclic, and Bicyclic Monoterpenes Group, which are a part of the larger Terpenes and Terpenoids Group.

Summary of publications
Substance group CAS RN Common name DSL name Draft screening assessment Risk management scope Proposed conclusion on section 64 criteria Follow-up activities
Acyclic, Monocyclic, and Bicyclic Monoterpenes Group 8015-77-8Table 1 footnote a,Table 1 footnote b Bois de rose oil Oils, bois de rose HTML None Does not meet None planned at this time
8014-19-5Table 1 footnote a,Table 1 footnote b Palmarosa oil Oils, palmarosa
8000-46-2Table 1 footnote a,Table 1 footnote b Geranium oil Oils, geranium
8008-52-4Table 1 footnote a Coriander oil Oils, coriander
8007-01-0Table 1 footnote a Rose oil Oils, rose HTML Meets one or more of the criteria Refer to risk management scope
8007-02-1Table 1 footnote a Lemongrass oil Oils, lemongrass None Does not meet None planned at this time
1113-21-9 Geranyllinalool 1,6,10,14-Hexadecatetraen-3-ol, 3,7,11,15-tetramethyl-, (E,E)-
8008-31-9Table 1 footnote a,Table 1 footnote b Mandarin oil Oils, mandarin HTML Meets one or more of the criteria Refer to risk management scope
8016-85-1Table 1 footnote a,Table 1 footnote b Tangerine oil Oils, tangerine
8008-57-9Table 1 footnote a Sweet orange oil Oils, orange, sweet None Does not meet None planned at this time
80-56-8 Alpha-pinene Bicyclo[3.1.1]hept-2-ene, 2,6,6-trimethyl-
8006-64-2Table 1 footnote a Turpentine oil Turpentine, oil HTML Meets one or more of the criteria Refer to risk management scope
9005-90-7Table 1 footnote a,Table 1 footnote b Turpentine Turpentine
8021-28-1Table 1 footnote a,Table 1 footnote b Fir oil Oils, fir None Does not meet None planned at this time
8002-09-3Table 1 footnote a Pine oil Oils, pine
Timelines
Date Activity
March 2021 Anticipated publication of the final screening assessment and proposed risk management approach.
March 14, 2020 Publication and start of 60-day public comment period on the Draft Screening Assessment for Terpenes and Terpenoids Acyclic, Monocyclic, and Bicyclic Monoterpenes Group and the Risk Management Scope for Certain Terpenes and Terpenoids within the Acyclic, Monocyclic and Bicyclic Monoterpenes Group, Specifically: Rose Oil, Mandarin Oil, Tangerine Oil, Turpentine Oil, and Turpentine. The related notice was published in the Canada Gazette, Part I: Vol. 154, No. 11.

Background

The screening assessment focuses on 15 substances referred to as the Acyclic, Monocyclic, and Bicyclic Monoterpenes Group. These substances are a part of a larger group of 76 substances referred to collectively under the CMP as the Terpenes and Terpenoids Group.

Three of these 76 substances were subsequently determined to be of low concern to both human health and the environment through other approaches. The conclusion for CAS RN 25428-43-7 is provided in the Final Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure. Conclusions for CAS RNs 29350-73-0 and 68916-97-2 are provided in the Final Screening Assessment of Substances Identified as Being of Low Concern using the Ecological Risk Classification of Organic Substances and the Threshold of Toxicological Concern (TTC)-based Approach for Certain Substances.

Sixteen of these 76 substances (CAS RNs 495-62-5, 8001-61-4, 8007-08-7, 17627-44-0, 65113-99-7, 107898-54-4, 87-44-5, 88-84-6, 3691-12-1, 4630-07-3, 68917-29-3, 489-86-1, 639-99-6, 22451-73-6, 8006-87-9, and 489-84-9) were assessed as a part of the Monocyclic and Bicyclic Sesquiterpenes Group.

Twelve of these 76 substances (CAS RNs 8006-78-8, 8016-88-4, 8022-96-6, 8024-43-9, 8024-08-6, 80-54-6, 91-51-0, 37677-14-8, 52474-60-9, 52475-86-2, 65405-84-7 and 66327-54-6) were assessed as a part of the Phenylpropanoids and Aldehydes Group.

Decisions on the remaining 30 substances will be communicated in separate risk assessments.

Page details

Date modified: